Robust Financials

The company’s balance sheet is strong, ending March 31 2026 with $844.9 million in cash and marketable securities. Earnings rose to 25 cents per share, beating consensus expectations of a 26‑cent loss. Immunocore trades at a price‑to‑sales multiple of 3.4 ×, a premium that hinges on sustained Kimmtrak growth and pipeline progress.